Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO ® ▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients
Kyowa Kirin International PLC (Kyowa Kirin), a wholly owned subsidiary of Kyowa Kirin Co., Ltd., today announced a new study of real world data showing higher response rates than previously seen in people living with cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO® (mogamulizumab). The findings, from a retrospective observational study of French CTCL patients, showed that the best overall response rate in the real-life study was 58.5 per cent, compared to 35 per cent seen in the MAVORIC trial.1,2 The MAVORIC study was the pivotal Phase 3 trial that investigated treatment with POTELIGEO® compared to an active comparatora in previously treated adult patients with mycosis fungoides (MF) and Sézary syndrome (SS), two types of CTCL.
Professor Martine Bagot of Saint-Louis Hospital, Université de Paris, France said: “The purpose of the study was to assess, for the first time, the efficacy and safety of mogamulizumab in a real-life setting. We saw a higher response in the real-life study compared to the MAVORIC trial results. The increase was also seen in both the MF and SS patient groups, compared to MAVORIC. As both the real world data and MAVORIC recruited a broadly similar set of patients, this new data underlines the value of mogamulizumab in treating these CTCL patients, whose disease causes a severe impact on their functioning, emotional and social wellbeing.”
Data was collected and analysed from medical records of 124 MF and SS patients treated with POTELIGEO between February 2014 and March 2020, from 14 specialist treatment centres in France. The best overall response rate (ORR) seen in the real-life study was 47.0% in MF patients and 68.3% in SS patients. In contrast, the ORRb in MAVORIC was 21% and 37%, respectively.1,2 Of the 124 patients who received POTELIGEO treatment in the study, 44% were MF patients and 56% were SS patients. This compares to 56% and 44% in MAVORIC, respectively. In the real-life study, 49.6% of patients were at disease stage IVA1, compared to 39% in MAVORIC.1,2
POTELIGEO was also shown to have a favourable safety profile, in the real life study the most common drug-related treatment-emergent adverse events (TEAEs) were lymphopenia and asthenia. Commonly occurring TEAEs seen in both the real life study and MAVORIC were rash and infusion-related reactions.1,2
Abdul Mullick, President of Kyowa Kirin International, said: “Kyowa Kirin is committed to improving outcomes for patients with rare diseases, whose needs are often underserved. It’s heartening to see this new real world data, which reinforces what we’ve seen previously in clinical trials. Kyowa Kirin is dedicated to improve the lives of patients with CTCL, which is a chronic, debilitating disease and to deliver on our purpose, to make people smile.”
MF and SS are subtypes of CTCL, a rare type of non-Hodgkin's lymphoma that can affect the skin, blood, lymph nodes and internal organs.3 It is associated with disfiguring skin lesions, intractable itching, sleep disturbance, and psychosocial problems, CTCL has a serious negative effect on quality of life.4
The new data was presented at a poster session at the EORTC meeting in Marseille, France, which is being held on 14-16 October 2021.
a The comparator in the MAVORIC trial was vorinostat, a histone deacetylase inhibitor (HDACi) and FDA-approved standard of care option for treatment of CTCL that is licensed in the US for the treatment of cutaneous manifestations in patients with CTCL who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat is not licensed for use in Europe.
b MAVORIC ORR included only those patients with confirmed global response at two (or more) successive evaluations at least 8 weeks apart).
About Mycosis Fungoides (MF) and Sézary syndrome (SS)
Cutaneous T-cell lymphoma (CTCL) is a cancer of white blood cells (lymphocytes) that presents in the skin.5 CTCLs are rare, serious and potentially life-threatening forms of non-Hodgkin lymphoma (NHL).2 Malignant T cells in CTCL circulate in the blood and migrate to the skin6 causing lesions and itching.7
The annual incidence of CTCL in Europe is around 5.2 new cases per 100,000 population8 and it affects around 240 people per million in the region at any one time.5 The two best-studied types of CTCL are mycosis fungoides (MF) and Sézary syndrome (SS).9 Together, MF and SS account for around two thirds of all CTCLs.10,11
- MF accounts for approximately 60% of all CTCLs,10 is typically indolent and is characterised by skin symptoms including patches or plaques, skin redness and tumours.12
- SS is much rarer, accounting for around 5% of CTCLs,6 and is more aggressive13 with high levels of blood involvement by definition.10 It causes very severe itching, total body redness (erythroderma), intense scaling of the skin and frequent hair loss. 7
It can typically take between three and six years from CTCL disease onset for a patient to be diagnosed, in some cases it can take decades.10,12 This is sometimes due to the fact that CTCL presents very similarly to other benign skin conditions (e.g. eczema and psoriasis)7; this can mean many patients experience a long, frustrating journey before diagnosis.
CTCL can be very distressing for patients and has a significant negative life-long impact upon many aspects of a patient’s life.12,14 CTCL causes chronic skin impairment with itching, pain, recurrent infections, and disfiguring skin lesions, as well as sleep disturbance and psychosocial problems.9,12 Even in the early stages of CTCL, the disease can affect patients’ ability to meet the needs of their family, interfere with their job, and limit normal daily activities.14
About POTELIGEO(mogamulizumab) and the MAVORIC Trial
Malignant T lymphocytes in MF and SS, consistently express a molecule called CC chemokine receptor 4 (CCR4).2 POTELIGEO is a humanised monoclonal antibody that selectively binds to CCR4-expressing cells15 and helps destroy them by harnessing the body’s immune system.2 POTELIGEO is a systemic therapy, administered by intravenous infusion weekly for the first five weeks, then subsequently every two weeks.15 The registrational Phase 3 MAVORIC trial was the largest randomised study of systemic therapy in CTCL. It evaluated the safety and efficacy of POTELIGEO versus vorinostat in patients who had failed at least one previous systemic therapy.2
Following a positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), the European Commission (EC) granted marketing authorisation for POTELIGEO in November 2018 for the treatment of adult patients with MF or SS who have received at least one prior systemic therapy.15
Important Prescribing information and Safety Information
Refer to the full Summary of Product Characteristics (SmPC) for prescribing information and the full safety information: https://www.ema.europa.eu/en/medicines/human/EPAR/poteligeo#product-information-section
About Kyowa Kirin
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ -years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/
Kyowa Kirin International
Galabank Business Park
Galashiels, TD1 1QH
1 Bagot, M et al. Poster presentation at EORTC, 14-16 October 2021.
2 Kim YH, et al. Lancet Oncol. 2018;19(9):1192–1204.
3 Olsen E, Vonderheid E, Pimpinelli N, et al. Blood. 2007;110(6):1713-22.
4 EHA 2021 abstract. Available at: HEALTH-RELATED QUALITY OF LIFE EFFECT OF MOGAMULIZUMAB BY PATIENT.... EHA Library. Bishton M. Jun 9 2021; 324119 (ehaweb.org). Accessed October 2021
5 Willemze R, et al. Blood. 2019;133(16):1703–1714
6 Girardi M, Heald PW, Wilson LD. N Engl Jnl Med. 2004; 350(19): 1978-1988
7 Demierre M, et al. Cancer. 2006;107(10):2504–2511
8 Orphanet. Prevalence and incidence of rare diseases: Bibliographic data. January 2021. Available at: https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf. Accessed: October 2021.
9 Krejsgaard T, et al. Semin Immunopathol. 2017;39:269–282.
10 Wilcox R. Am J Hematol. 2016;91(1):151-165.
11 Trautinger F, et al. Eur J Cancer. 2017;77:57–74.
12 Scarisbrick J, et al. Br J Dermatol. 2019;181(2):350–357.
13 Lymphoma Coalition. Cutaneous lymphoma – a patient’s guide. Available at: https://lymphomacoalition.org/wp-content/uploads/Cutaneous_lymphoma_-_patients_guide_-.pdf. Accessed October 2021
14 Hirstov AC, Tejavsi T, Wilcox RA. Am J Hematol. 2019;(734):ajh.25577
15 POTELIGEO SMPC. Available at: https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_en.pdf. Accessed October 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contacts for Kyowa Kirin International:
+44 (0) 7769 656073
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deel Raises $425M in Series D Funding to Continue Transforming the Future of Work18.10.2021 14:45:00 CEST | Press release
Deel, the remote hiring company shattering job barriers worldwide, announced today that it has raised $425 million in Series D funding, taking the total amount raised by the company to over $630 million. The latest funding round values the company at $5.5 billion. Deel has become the highest valued company in the global hiring, payments, and compliance space with this investment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005567/en/ Deel Interface (Graphic: Business Wire) This new funding round was led by US-based Coatue, with partners Rahul Kishore and Lucas Swisher leading the deal. Several new and existing investors also participated in this round, including Altimeter Capital, Andreessen Horowitz, the YC Continuity Fund, Spark Capital, Greenbay Ventures, Neo, and over 40 of the world’s leading operators. Since Deel’s inception in 2019, the team - growing from four to 400 employees - has been on a mission to make
William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today18.10.2021 14:30:00 CEST | Press release
Everbridge, Inc. (NASDAQ: EVBG) today announced the launch of its podcast Unlocking Resilience™: Global Leadership Seriesfeaturing William Shatner as its inaugural guest. The first-of-its-kind podcast features global influencers, government leaders, C-level executives and top healthcare experts as they discuss the confluence of leadership, technology and resilience at both the personal and organizational level. Topics will include overcoming personal challenges to create a life of resilience; effective strategies for building organizational resilience and business continuity in the face of critical events; and perspectives on the future of work, life and entertainment in a post-pandemic world, among other topics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005565/en/ William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today (Graphic: Business Wire) The Unlocking R
Ferring to Present Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection and IBD at ACG 202118.10.2021 14:00:00 CEST | Press release
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology’s Annual Scientific Meeting & Postgraduate Course (ACG 2021). The congress will take place in Las Vegas from October 22 – 27, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005060/en/ Eligibility criteria in CDI clinical trials often are narrowly defined, excluding broader patient populations. The first presentation will explore key health outcomes of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent C. difficile infection (CDI), among patients in a real-world setting. The second analysis evaluates healthcare resource utilization and medical costs among Medicare patients with CDI with or without inflammatory bowel disease (IBD) as a comorbidity. Notably, one of the presentations has received The
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes18.10.2021 13:30:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive Day 90 data for the first patient from the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). This is the first demonstration of a patient with T1D achieving robust restoration of islet cell function from such a cell therapy. The patient was treated with a single infusion of VX-880 at half the target dose in conjunction with immunosuppressive therapy. The patient achieved successful engraftment and demonstrated rapid and robust improvements in multiple measures, including increases in fasting and stimulated C-peptide, improvements in glycemic control, including HbA1c, and decreases in exogenous insulin requirement. VX-880 was generally well tolerated. “These results from the first patient treated with VX-880 are unprecedented. What makes these results truly remarkable is that they were ac
Industrial Flow Solutions™ Announces Deal to Acquire Clearwater Controls™ to Grow IoT Solutions for Wastewater Network Management, Increase Demand for Industry-Leading DERAGGER ™ +18.10.2021 13:06:00 CEST | Press release
Leading industrial pumping solutions provider Industrial Flow Solutions™, headquartered in New Haven, Conn., USA, announced today the agreement to acquire Clearwater Controls Ltd.™, based in Glasgow, Scotland. Clearwater Controls offers a broad line of wastewater solutions, beginning with its leading deragging intelligent systems to solve specific pumping problems, to more advanced monitoring technology to optimize and manage entire water networks. Terms of the acquisition were not disclosed. Clearwater Controls will retain its company name and brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005200/en/ Clearwater Controls' DERAGGER™ products offer intelligent efficiency and the end of ragging. Industrial Flow Solutions has announced a deal to acquire Clearwater Controls to grow IoT solutions for wastewater network management. Clearwater Controls offers a broad line of wastewater solutions, beginning with its lead
ThreatConnect Releases Risk Quantifier™ 6.0 — Driving Continued Innovation in Cyber Risk Quantification18.10.2021 12:30:00 CEST | Press release
ThreatConnect Inc.®, the leader in reducing complexity and enabling better decision making in cybersecurity, today released ThreatConnect Risk Quantifier™ 6.0 (RQ 6.0), continuing its innovation in the emerging field of cyber risk quantification. ThreatConnect Risk Quantifier™ (RQ) enables companies to see the financial risks they face from cyber attacks and also prioritize investments that provide the best ROI. RQ’s calculations are informed by your internal environment, threat intelligence, vulnerability management, operations and response data found within ThreatConnect and other integrations. RQ is distinctly different from other approaches offered in the market as it focuses on automation and data integration, and delivers value in days and weeks as opposed to months and years. With RQ 6.0 organizations that are looking at financial cyber risk quantification will have the option of leveraging full FAIR scenario’s, using semi-automated FAIR scenario’s, and full automation in one pl
Technology Innovation Institute’s Directed Energy Research Centre becomes First-in-Region to Replicate Electromagnetic Pulses from High-altitude Nuclear Reaction18.10.2021 11:28:00 CEST | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Centre (DERC) has become the first such entity in the region capable of reproducing the high-altitude electromagnetic pulses (HEMP) generated during nuclear reaction in high altitudes at its electromagnetic compatibility (EMC) labs. The Nuclear Electromagnetic Pulse Simulator offers critical infrastructures, service providers, and research institutions in the UAE and wider GCC region greater autonomy when it comes to testing - a function that needed to earlier be outsourced abroad. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005404/en/ Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre (Photo: AETOSWire) DERC’s EMC labs comprise a modular semi-anechoic chamber that enables testing to evaluate susceptibility of electronics to